

Wednesday, December 7th, 2016

DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

Wolf DM, Yau C, Sanil A, Glas A, Petricoin C, Wulfkuhle J, Brown-Swigart L, Hirst G, I-SPY 2 TRIAL Investigators, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olapade O, van 't Veer L. University of California, San Francisco; Berry Consultants, LLC; Agendia, Inc; George Mason University; QuantumLeap Healthcare Collaborative; University of Pennsylvania; University of Texas, MD Anderson; University of Minnesota; University of Chicago; Equal Contribution

Session Title: *Breast Cancer Genomics: From the Individual to the Human Population*

Session Time: 4:30 PM

Location: GENERAL SESSION 2, Hall 3

Program Number: S2-06 (P1-09-07 moved from Poster Session 1)

An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

Gavin PG, Kim PS, Lipchick C, Langley E, Feng H, Meyer GR, Rim Kim S, Michel JP, Jacobs SA, Srinivasan A, Pogue-Geile KL. NSABP Foundation; DiaTech Oncology.

Session Title: *Tumor Cell and Molecular Biology: Molecular Profiles*

Session Time: 5:00 PM – 7:00 PM

Location: POSTER SESSION 1, Hall 1

Program Number: P1-07-12

Friday, December 9th, 2016

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Cardoso F, Slaets L, de Snoo F, Bogaerts J, van 't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Russo L, Dell'Orto P, Viale G. Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal; European Organization for Research and Treatment of Cancer, Brussels, Belgium; Medical Affairs, Agendia, Amsterdam, Netherlands; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; Netherlands Cancer Institute, Amsterdam, Netherlands; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; European Institute of Oncology (IEO) and University of Milan, Milan, Italy.

Session Title: *Multi Gene Markers and Decision Making*

Session Time: 7:30 AM – 9:00 AM

Location: POSTER DISCUSSION 7, Stars at Night Ballroom 1 & 2 – 3rd level

Program Number: PD7-01

Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20 year outcomes

Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS. University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of North Carolina; Karolinska Institutet and University Hospital, Solna, Sweden; Linöping University, Sweden.

Session Title: *Multi Gene Markers and Decision Making*

Session Time: 7:30 AM – 9:00 AM

Location: POSTER DISCUSSION 7, Stars at Night Ballroom 1 & 2 – 3rd level

Program Number: PD7-02

Agendia Poster Presentations

San Antonio Breast Cancer Symposium 2016



Friday, December 9th, 2016 (cont.)

MINT trial yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subtype

Blumencranz LE, Shivers SC, Untch S, Treece TD, Yoder E, Blumencranz PW, Cox CE. Agendia, Irvine, CA; USF Health, Tampa, FL; Morton Plant Hospital, Clearwater, FL

Session Title: *Treatment: Neoadjuvant Chemotherapy*

Session Time: 5:00 PM- 7:00 PM

Location: POSTER SESSION 5, Hall 1

Program Number: P5-16-05

Measuring the impact of MammaPrint on treatment in breast cancer patients: A prospective registry (IMPACT)

Soliman H, Untch S, Blumencranz L. Moffitt Cancer Center, Tampa, FL; Agendia Inc., Irvine, CA.

Session Title: *Treatment: Ongoing Trials -Predictive & Prognostic Factors*

Session Time: 5:00 PM- 7:00 PM

Location: POSTER SESSION OT3, Hall 1

Program Number: OT3-04-05

Saturday, December 10th, 2016

Impact of 70-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony Triple A study

Kuijjer A, Straver M, Elias S, Smorenburg C, Wesseling J, Linn S, Rutgers E, Siesling S, van Dalen T. Diaconessenhuis, Utrecht, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.

Session Title: *Prognostic and Predictive Factors - Other*

Session Time: 7:30 AM – 9:00 AM

Location: POSTER SESSION 6, Hall 1

Program Number: P6-09-03

Results of multigene assay (MammaPrint®) and molecular subtyping (Blueprint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Griesinger F, Koehler A, Otremba B, Schindlbeck C, Reimer T, Krauter J, Tome O, Otto F, Friedrichs K, Albert U-S, Gebauer G, Nitz U, Harbeck N. University Hospital Munich, CCC Munich, Munich, Germany; WSG, Moenchengladbach, Germany; Agendia, Amsterdam, Netherlands; Others, Germany; Others, Austria; Others, Switzerland.

Session Title: *Prognostic and Predictive Factors - Other*

Session Time: 7:30 AM – 9:00 AM

Location: POSTER SESSION 6, Hall 1

Program Number: P6-09-10

Long-term follow-up of early stage breast cancer patients with results of MammaPrint®, Oncotype DX® and MammoStrat® risk classification assays

Shivers SC, Russell S, Blumencranz L, Mehindru A, Acs G, Ellis D, Vrcelj V, Zanchi A, Blumencranz PW, Carter E, King J, Cox CE. Morsani College of Medicine at the University of South Florida (USF), Tampa, FL; Agendia, Inc., Irvine, CA; Florida Hospital Tampa, Tampa, FL; Morton Plant Hospital, Clearwater, FL.

Session Title: *Prognostic and Predictive Factors - Other*

Session Time: 7:30 AM – 9:00 AM

Location: POSTER SESSION 6, Hall 1

Program Number: P6-09-45